Myriad Genetics, Inc. (MYGN) fair value analysis
Nasdaq · Updated 2026-10-19
MYGN price how computed
Valuation status
No fair-value estimate yetMYGN has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for MYGN yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $3.98
- Sector
- Healthcare
- 12-month range
- $2.86–$8.18
- Market cap
- $381M
- From 52-week high
- -51.3%
- Shares outstanding
- 95.6M
- Rank in Healthcare by quality score
- #201 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Myriad Genetics, Inc. is a molecular diagnostics company that develops and commercializes genetic testing and precision medicine products for detecting hereditary cancers, common cancers, and other diseases. The company operates laboratories and serves patients across the United States and internationally through its various diagnostic testing platforms and services.
MYGN currently ranks #201 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $381M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $807M
- Net margin
- -14.0%
- EPS (TTM)
- $-0.67
- Gross margin
- 66.6%
- Debt / equity
- 0.69
- Revenue growth (3-yr avg)
- -0.2%
- Shares outstanding
- 95.6M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 45 · neutral
- 50-day average
- $3.67
- 200-day average
- $4.63
- Moving-average state
- 50-day below 200-day (death cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2009-06-15)
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 4 beat, 4 missed
- Quarter by quarter
- 2026-06 ▼ miss (-312.5%)
2026-03 ▼ miss (-28.6%)
2025-12 ▲ beat (+332.6%)
2025-09 ▼ miss (-2800.0%)
2025-06 ▲ beat (+600.0%)
2025-03 ▲ beat (+40.0%)
2024-12 ▼ miss (-1.0%)
2024-09 ▲ beat (+200.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 1 buy · 5 hold · 3 sell (9 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $4.11
- Target vs last price
- +3.3%
What our data shows for MYGN
- Shares are trading in the lower third of their 12-month price range of $2.86–$8.18.
- The 14-day relative strength index sits at a neutral 45.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MYGN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the MYGN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — # MYGN - TickrTrends Indicator Summary TickrTrends' derived indicators for MYGN showed a shift in momentum this week as the relative strength index moved from overbought territory into neutral zone, suggesting a moderation in price momentum after the previous week's stronger positioning. The stock remains in the healthcare sector with a valuation verdict currently awaiting full analysis.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is MYGN stock undervalued?
TickrTrends has no fair-value estimate for MYGN yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is MYGN's TickrTrends verdict?
MYGN is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does MYGN compare to other Healthcare stocks?
MYGN ranks #201 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MYGN overbought or oversold?
MYGN's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does MYGN pay a dividend?
MYGN has paid no dividend in the last twelve months; its last ex-dividend date on file was 2009-06-15.
When does MYGN report earnings next?
MYGN's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does MYGN usually beat earnings estimates?
Over its last 8 reported quarters MYGN beat the consensus estimate 4 times and missed 4 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MYGN?
Of 9 analysts covering MYGN, 1 rate it a buy, 5 a hold and 3 a sell - hold-leaning, with a consensus price target of $4.11 (+3.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.